| pubmed-article:19478395 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19478395 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:19478395 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:19478395 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:19478395 | lifeskim:mentions | umls-concept:C2003941 | lld:lifeskim |
| pubmed-article:19478395 | lifeskim:mentions | umls-concept:C1524075 | lld:lifeskim |
| pubmed-article:19478395 | lifeskim:mentions | umls-concept:C0337112 | lld:lifeskim |
| pubmed-article:19478395 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:19478395 | pubmed:dateCreated | 2009-5-29 | lld:pubmed |
| pubmed-article:19478395 | pubmed:abstractText | Human interleukin-5 is the key cytokine involved in regulating the production and function of human eosinophils. IL-5 binds to its specific receptor composed of two heterogeneous alpha and beta polypeptide chains (hIL-5Ralpha and betac) that are expressed on the cell surface. The hIL-5Ralpha specifically binds IL-5 without involvement of the betac. It has been suggested that neutralizing antibodies to hIL-5Ralpha could serve as a therapeutic agent in eosinophil-associated diseases. We describe here the creation and biologic activities of a mouse monoclonal antibody against hIL-5Ralpha that blocks the following IL-5 dependent activities (a) binding of the IL-5 ligand to its receptor, (b) IL-5 dependent growth of hIL-5R expressing cells, and (c) IL-5-induced adhesion of human eosinophils. We also describe the process for humanization of the mouse Mab towards development of a therapeutic MAb. The humanized version of the monoclonal antibody also displayed potent neutralizing activity against IL-5 dependent activities. | lld:pubmed |
| pubmed-article:19478395 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19478395 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19478395 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19478395 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19478395 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19478395 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19478395 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19478395 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19478395 | pubmed:issn | 1093-2607 | lld:pubmed |
| pubmed-article:19478395 | pubmed:author | pubmed-author:TakatsuKiyosh... | lld:pubmed |
| pubmed-article:19478395 | pubmed:author | pubmed-author:AnazawaHideha... | lld:pubmed |
| pubmed-article:19478395 | pubmed:author | pubmed-author:HanaiNobuoN | lld:pubmed |
| pubmed-article:19478395 | pubmed:author | pubmed-author:NakamuraKazuy... | lld:pubmed |
| pubmed-article:19478395 | pubmed:author | pubmed-author:FuruyaAkikoA | lld:pubmed |
| pubmed-article:19478395 | pubmed:author | pubmed-author:KoikeMasamich... | lld:pubmed |
| pubmed-article:19478395 | pubmed:author | pubmed-author:IidaAkihoroA | lld:pubmed |
| pubmed-article:19478395 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19478395 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:19478395 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19478395 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19478395 | pubmed:pagination | 17-27 | lld:pubmed |
| pubmed-article:19478395 | pubmed:meshHeading | pubmed-meshheading:19478395... | lld:pubmed |
| pubmed-article:19478395 | pubmed:meshHeading | pubmed-meshheading:19478395... | lld:pubmed |
| pubmed-article:19478395 | pubmed:meshHeading | pubmed-meshheading:19478395... | lld:pubmed |
| pubmed-article:19478395 | pubmed:meshHeading | pubmed-meshheading:19478395... | lld:pubmed |
| pubmed-article:19478395 | pubmed:meshHeading | pubmed-meshheading:19478395... | lld:pubmed |
| pubmed-article:19478395 | pubmed:meshHeading | pubmed-meshheading:19478395... | lld:pubmed |
| pubmed-article:19478395 | pubmed:meshHeading | pubmed-meshheading:19478395... | lld:pubmed |
| pubmed-article:19478395 | pubmed:meshHeading | pubmed-meshheading:19478395... | lld:pubmed |
| pubmed-article:19478395 | pubmed:meshHeading | pubmed-meshheading:19478395... | lld:pubmed |
| pubmed-article:19478395 | pubmed:meshHeading | pubmed-meshheading:19478395... | lld:pubmed |
| pubmed-article:19478395 | pubmed:meshHeading | pubmed-meshheading:19478395... | lld:pubmed |
| pubmed-article:19478395 | pubmed:meshHeading | pubmed-meshheading:19478395... | lld:pubmed |
| pubmed-article:19478395 | pubmed:meshHeading | pubmed-meshheading:19478395... | lld:pubmed |
| pubmed-article:19478395 | pubmed:meshHeading | pubmed-meshheading:19478395... | lld:pubmed |
| pubmed-article:19478395 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19478395 | pubmed:articleTitle | Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. | lld:pubmed |
| pubmed-article:19478395 | pubmed:affiliation | Tokyo Research Laboratories, Kyowa Hakko Kirin, Co., Ltd, Machida-shi, Tokyo, Japan. masamichi.koike@biowa.com | lld:pubmed |
| pubmed-article:19478395 | pubmed:publicationType | Journal Article | lld:pubmed |
